Original Article
Natural History of Paroxysmal Nocturnal Hemoglobinuria
N Engl J Med 1995; 333:1253-1259November 9, 1995
- Abstract
Background
Paroxysmal nocturnal hemoglobinuria (PNH), which is characterized by intravascular hemolysis and venous thrombosis, is an acquired clonal disorder associated with a somatic mutation in a totipotent hematopoietic stem cell. An understanding of the natural history of PNH is essential to improve therapy.
Methods
We have followed a group of 80 consecutive patients with PNH who were referred to Hammersmith Hospital, London, between 1940 and 1970. They were treated with supportive measures, such as oral anticoagulant therapy after established thromboses, and transfusions.
Results
The median age of the patients at the time of diagnosis was 42 years (range, 16 to 75), and the median survival after diagnosis was 10 years, with 22 patients (28 percent) surviving for 25 years. Sixty patients have died; 28 of the 48 patients for whom the cause of death is known died from either venous thrombosis or hemorrhage. Thirty-one patients (39 percent) had one or more episodes of venous thrombosis during their illness. Of the 35 patients who survived for 10 years or more, 12 had a spontaneous clinical recovery. No PNH-affected cells were found among the erythrocytes or neutrophils of the patients in prolonged remission, but a few PNH-affected lymphocytes were detectable in three of the four patients tested. Leukemia did not develop in any of the patients.
Conclusions
PNH is a chronic disorder that curtails life. A spontaneous long-term remission can occur, which must be taken into account when considering potentially dangerous treatments, such as bone marrow transplantation. Platelet transfusions should be given, as appropriate, and long-term anticoagulation therapy should be considered for all patients.
Media in This Article
Figure 2
Actuarial Survival from the Time of Diagnosis in 80 Patients with PNH.Figure 1
Course of Illness in 80 Consecutive Patients with PNH.Article Activity
- Article
Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired disorder of hematopoiesis characterized by intravascular hemolysis and manifested by episodes of hemoglobinuria and life-threatening venous thromboses.1 The cellular abnormality in this disorder is caused by a somatic mutation in a totipotent hematopoietic stem cell.2,3 The cells derived from the abnormal clone are deficient in all surface proteins normally attached to the cell membrane by a glycosylphosphatidylinositol anchor.4,5
PNH was first described as a distinct clinical entity in 1882.6 The cardinal diagnostic test, introduced in the late 1930s, is Ham's test,7 which is based on the increased sensitivity of PNH-affected erythrocytes to lysis by complement. deficiency of an antigen known as the membrane inhibitor of reactive lysis (CD59) is largely responsible for the hemolysis8,9 and is implicated in the tendency for patients to have thromboses.9 In the past two years the biochemical defect underlying PNH has been pinpointed at an early step in the biosynthesis of glycosylphosphatidylinositol molecules — namely, the transfer of N-acetylglucosamine to phosphatidylinositol.10-12 The protein required for this step is encoded by a gene, PIG-A, that is somatically mutated in patients with PNH.13-17
Despite the remarkable progress in our understanding of this disorder, treatment has remained largely supportive. The only potentially curative therapy currently available is bone marrow transplantation,18,19 which is associated with substantial morbidity and mortality.20 To determine whether the management of PNH can be improved, it is important to know its natural history. We report the results of a long-term study (up to 48 years after the diagnosis) of a group of 80 patients with PNH seen at one institution between 1940 and 1970. This study has uncovered some surprising information on the natural history of the disorder and has identified relatively simple therapies that may reduce the associated morbidity and mortality.
Methods
Patients
Eighty patients with PNH were referred to Hammersmith Hospital in London between 1940 and 1970. In all patients the diagnosis was established or confirmed by a positive Ham's test.21 This group of patients was last described in 1972.22 Follow-up data have been obtained by contacting the patients' primary physicians and reviewing death certificates.
Complications and Causes of Death
The complications and causes of death reported were either unequivocally diagnosable on clinical grounds or were diagnosed after death. If a complication was not confirmed, it is not reported here. Thus, the reported incidence of complications is likely to be an underestimate, because many of the patients were seen at Hammersmith Hospital only infrequently. We compared the survival of the patients with the survival of a control group matched for sex and age.
Analysis of Blood Samples
In 1993 venous blood samples were obtained from five patients in either acid–citrate–dextrose or EDTA for the performance of Ham's tests and flow cytometric studies of the expression of glycosylphosphatidylinositol-linked proteins on erythrocytes and white cells, as previously described.23,24 By definition, normal cells express normal levels of glycosylphosphatidylinositol-linked proteins, whereas PNH-affected cells are deficient in all these proteins.
Results
Follow-up Studies
Sixty of the 80 patients were known to have died, and 6 patients were lost to follow-up before 1972. The remaining 14 patients were alive when last seen between 1975 and 1994, and 9 of the 14 were known to be alive in 1994.
Clinical Presentation
The presenting features or initial diagnoses were reported previously.22 The median age at the time of diagnosis was 42 years (range, 16 to 75). Forty-three (84 percent) of the 51 patients for whom reliable information was available had episodes of hemoglobinuria as a chief symptom at some time during their illness.
Course of Illness and Survival
The course of the disease in each of the 80 patients is shown in Figure 1Figure 1
Course of Illness in 80 Consecutive Patients with PNH.. From the actuarial survival curve for the group, we calculated a median survival of approximately 10 years (Figure 2Figure 2Actuarial Survival from the Time of Diagnosis in 80 Patients with PNH.). Twenty-five years after the diagnosis, 58 patients (72 percent) had died, and 22 (28 percent) were alive. The median age at the time of death was 56 years (range, 20 to 84), with a median interval of 10 years (range, 0 to 48) between diagnosis and death. Patient 10 received the diagnosis of PNH in 1939, had a spontaneous remission in 1949, and died of bronchial carcinoma in 1987, 48 years after the diagnosis.Cause of Death
For 12 of the 60 patients who died (Table 1Table 1
Causes of Death in 60 Patients with PNH.), the cause of death was unknown. In 28 of the other 48 patients (58 percent), the cause of death (either thrombosis or hemorrhage attributable to thrombocytopenia) was directly related to PNH. In the other 20 patients (42 percent), the cause of death was unrelated to PNH.Venous Thrombosis
Thirty-one patients (39 percent) were known to have had one or more episodes of venous thrombosis during the course of their illness (Table 2Table 2
Sites and Types of Thrombosis.), and several patients had repeated thromboses. In many patients the thrombosis was either fatal or life-threatening, and it was often unheralded.Spontaneous Remission
Twelve patients (15 percent) had spontaneous clinical remissions (Figure 1), with negative Ham's tests in all nine who were tested. We later obtained blood samples from five of these nine patients; in all five the erythrocytes expressed normal levels of glycosylphosphatidylinositol-linked proteins, with no demonstrable PNH-affected erythrocytes (Figure 3AFigure 3
Flow-Cytometric Analysis of Blood Cells from a Normal Subject and Patient 14 after Spontaneous Recovery from PNH.). In addition, of the four patients tested, none had PNH-affected neutrophils (Figure 3A), but three of the four had small numbers of PNH-affected lymphocytes (Figure 3B). Further analysis by double fluorescent staining demonstrated a subpopulation of PNH-affected lymphocytes among CD4+ T cells, CD8+ T cells, and CD19+ B cells in all three patients.Associated Disorders
Twenty-three patients (29 percent) received a diagnosis of aplastic anemia before the diagnosis of PNH. Nine of these patients subsequently had hemolytic PNH, with episodes of overt hemoglobinuria, and six did not; whether the remaining eight patients ever had hemoglobinuria could not be reliably determined.
At the time of the diagnosis, 64 of the 80 patients (80 percent) had thrombocytopenia (platelet count, <150,000 per cubic millimeter), and 38 patients (48 percent) had severe thrombocytopenia (platelet count, <50,000 per cubic millimeter). In addition, 44 patients (55 percent) had neutropenia (neutrophil count, <1500 per cubic millimeter).
In five patients the disorder progressed from hemolytic PNH to aplasia. Ham's test remained positive in four of these patients, but the fifth (Patient 34) subsequently had a negative Ham's test, with no PNH-affected erythrocytes or neutrophils. The patient died from bleeding due to severe thrombocytopenia 37 years after the diagnosis of PNH and at least 8 years after Ham's test had become negative.
Leukemia was not known to have developed in any of the patients.
Discussion
Clinical Features
In this group of 80 patients who were followed for up to 48 years, the median actuarial survival was 10 years, with 28 percent of the patients surviving for 25 years. Death was directly attributable to PNH or to bone marrow hypoplasia in 58 percent of the patients who died. Therapy with platelet concentrates should reduce mortality from hemorrhage due to thrombocytopenia.
At least 39 percent of the patients had venous thrombosis at some time during their illness. Many patients had initial thromboses that were life-threatening, but two (Patients 17 and 70), who probably had postpartum hepatic-vein thrombosis, recovered and survived for 34 and 27 years, respectively, after the thrombosis. One other patient (Patient 34) survived for 24 years after a thrombosis of the inferior mesenteric vein.
Spontaneous Remission
In some patients with PNH, the severity of the illness diminishes with time,25 and some patients have a complete clinical remission,22,26 although laboratory abnormalities may persist for years.27 In this series 15 percent of the patients had spontaneous clinical remissions, and Ham's test became negative in the patients who were tested. Neither the severity of symptoms or complications nor the proportion of red cells lysed in Ham's test was correlated with an eventual remission. Among the patients with remissions, one (Patient 14) had severe, transfusion-dependent PNH and thromboses, and at least two had over 50 percent lysis in earlier Ham's tests, suggesting that they had few residual normal stem cells at the height of their illness. The spontaneous remissions occurred between 10 and 20 years after the diagnosis of PNH. Of the 35 patients who survived 10 years or more, 12 (34 percent) eventually had remissions. A possible explanation for spontaneous remission is that the clones of PNH-affected cells have a finite life span, like normal somatic cells. Recovery may thus depend on the presence of normal stem cells capable of repopulating the bone marrow.28
There were no erythrocytes or neutrophils affected by PNH after recovery, but three of four patients tested had some residual abnormal lymphocytes. These results are consistent with the fact that lymphocytes have a much longer life span than myeloid and erythroid cells and that committed lymphocyte progenitor cells undergo division less frequently than the other cells. If the aging process postulated as being responsible for the gradual disappearance of clones of PNH-affected cells is related to the number of cell divisions, this may explain why abnormal lymphocytes persist for many years after the disappearance of abnormal neutrophils and erythrocytes.
Pnh and Bone Marrow Failure
The data on this series of patients provide further evidence of the close relation between PNH and aplastic anemia. The coexistence of the two conditions in one patient was first reported in 1944,29 with subsequent reports in 195230 and 1961.31 Cultures of peripheral blood and bone marrow from patients with PNH consistently show reduced numbers of erythroid progenitor cells (erythroid burst-forming units) and myeloid progenitor cells (granulocyte–macrophage colony-forming units), even in the absence of pancytopenia,32,33 as in patients with aplastic anemia.34 In addition, PNH eventually develops in 10 to 31 percent of patients with aplastic anemia treated with immunosuppressive agents.35 It is important to emphasize that PNH is not a complication of immunosuppressive treatment. Instead, the majority of patients with this disorder probably have an underlying aplastic process. Clones of PNH-affected cells may thus have a relative growth or survival advantage over the residual normal bone marrow in patients who have aplastic anemia.1,28,36 It is conceivable that the mutation leading to the development of PNH occurs quite frequently but that, in the absence of marrow hypoplasia, the clone has difficulty establishing itself.28
Pnh and Leukemia
Because of the reports of myelodysplasia and leu-kemia1 — invariably, acute myeloid leukemia — in patients with PNH, it has been regarded as a preleukemic condition. Leukemia did not develop in any of our 80 patients, however, indicating that it is relatively rare in unselected patients with PNH. Acute myeloid leukemia eventually develops in approximately 5 percent of patients with aplastic anemia who survive the marrow aplasia.35 Thus, aplastic anemia may predispose patients to both PNH and acute myeloid leukemia, but the development of PNH may not add to the risk of leukemia associated with uncomplicated aplastic anemia.
In most reported cases of leukemia in patients with PNH in whom the leukemic cells were studied,37,38 the leukemic clone was derived from the PNH clone. According to a recent report of a patient with PNH who subsequently had a myelodysplastic syndrome, the blasts expressed normal levels of glycosylphosphatidylinositol-linked proteins,39 indicating that the leukemic event may occur in the residual normal stem cells.
Management
The natural history of PNH is an important factor in decisions about therapy for individual patients. Thrombolytic treatment of hepatic-vein thrombosis with tissue plasminogen activator has been reported to be effective.40 Oral anticoagulation therapy after venous thrombosis has been used since the 1950s.25 In view of the high incidence of potentially fatal thrombosis, a strong case can be made for prophylactic anticoagulation treatment in all patients with PNH in whom there is no contraindication (such as severe thrombocytopenia). This approach may improve survival and reduce morbidity.
The only curative therapy at present is bone marrow transplantation, but it is available to only a small proportion of patients and is associated with substantial morbidity and mortality. The recent advances in the understanding of the pathogenesis of PNH and, in particular, of the molecular lesion open opportunities to explore new treatments, such as gene therapy. The possibility of spontaneous remission and of long-term survival must be taken into account when considering either bone marrow transplantation or other new treatments for this disorder.
Supported by grants from the Wellcome Trust, the Annette Fox Leukaemia Research Fund, and the Friends of the Leukaemia Unit, Leeds General Infirmary.
We are indebted to the late Miss Eleanor Lloyd for her assistance in this project, to the patients, and to the physicians who originally referred the patients and provided follow-up data.
Source Information
From the Department of Haematology, Royal Postgraduate Medical School and Hammersmith Hospital, London (P.H., S.M.L., M.B., L.L., J.V.D.); the Haematological Malignancy Diagnostic Service, Institute of Pathology, General Infirmary at Leeds, Leeds, United Kingdom (P.H.); and the Department of Human Genetics, Memorial Sloan-Kettering Cancer Center, New York (M.B., L.L.).
Address reprint requests to Dr. Hillmen at the Haematological Malignancy Diagnostic Service, Institute of Pathology, General Infirmary at Leeds, Great George St., Leeds LS1 3EX, United Kingdom.
- References
References
1
Rotoli B ,Luzzatto L . Paroxysmal nocturnal haemoglobinuria. Baillieres Clin Haematol 1989;2:113-138
CrossRef | Medline2
Dacie JV . Paroxysmal nocturnal haemoglobinuria. Proc R Soc Med 1963;56:587-596
Medline3
Oni SB ,Osunkoya BO ,Luzzatto L . Paroxysmal nocturnal hemoglobinuria: evidence for monoclonal origin of abnormal red cells. Blood 1970;36:145-152
Web of Science | Medline4
Ferguson MAJ . Glycosyl-phosphatidylinositol membrane anchors: the tale of a tail. Biochem Soc Trans 1992;20:243-256
Web of Science | Medline5
Rosse WF . Phosphatidylinositol-linked proteins and paroxysmal nocturnal hemoglobinuria. Blood 1990;75:1595-1601
Web of Science | Medline6
Crosby WH . Paroxysmal nocturnal hemoglobinuria: a classic description by Paul Strübing in 1882, and a bibliography of the disease. Blood 1951;6:270-284
Web of Science | Medline7
Rosse WF . Dr. Ham's test revisited. Blood 1991;78:547-550
Web of Science | Medline8
Holguin MH ,Fredrick LR ,Bernshaw NJ ,Wilcox LA ,Parker CJ . Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria. J Clin Invest 1989;84:7-17
CrossRef | Web of Science | Medline9
Yamashina M ,Ueda E ,Kinoshita T , et al. Inherited complete deficiency of 20-kilodalton homologous restriction factor (CD59) as a cause of paroxysmal nocturnal hemoglobinuria. N Engl J Med 1990;323:1184-1189
Full Text | Web of Science | Medline10
Armstrong C ,Schubert J ,Ueda E , et al. Affected paroxysmal nocturnal hemoglobinuria T lymphocytes harbor a common defect in assembly of N-acetyl-D-glucosamine inositol phospholipid corresponding to that in class A Thy-1- murine lymphoma mutants. J Biol Chem 1992;267:25347-25351
Web of Science | Medline11
Hillmen P ,Bessler M ,Mason PJ ,Watkins WM ,Luzzatto L . Specific defect in N-acetylglucosamine incorporation in the biosynthesis of the glycosylphosphatidylinositol anchor in cloned cell lines from patients with paroxysmal nocturnal hemoglobinuria. Proc Natl Acad Sci U S A 1993;90:5272-5276
CrossRef | Web of Science | Medline12
Takahashi M ,Takeda J ,Hirose S , et al. Deficient biosynthesis of N-acetylglucosaminyl-phosphatidylinositol, the first intermediate of glycosyl phosphatidylinositol anchor biosynthesis, in cell lines established from patients with paroxysmal nocturnal hemoglobinuria. J Exp Med 1993;177:517-521
CrossRef | Web of Science | Medline13
Miyata T ,Takeda J ,Iida Y , et al. The cloning of PIG-A, a component in the early step of GPI-anchor biosynthesis. Science 1993;259:1318-1320
CrossRef | Web of Science | Medline14
Takeda J ,Miyata T ,Kawagoe K , et al. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell 1993;73:703-711
CrossRef | Web of Science | Medline15
Bessler M ,Mason PJ ,Hillmen P , et al. Paroxysmal nocturnal haemoglobinuria (PNH) is caused by somatic mutations in the PIG-A gene. EMBO J 1994;13:110-117
Web of Science | Medline16
Miyata T ,Yamada N ,Iida Y , et al. Abnormalities of PIG-A transcripts in granulocytes from patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 1994;330:249-255
Full Text | Web of Science | Medline17
Bessler M ,Mason PJ ,Hillmen P ,Luzzatto L . Somatic mutations and cellular selection in paroxysmal nocturnal haemoglobinuria. Lancet 1994;343:951-953
CrossRef | Web of Science | Medline18
Storb R ,Evans RS ,Thomas ED , et al. Paroxysmal nocturnal haemoglobinuria and refractory marrow failure treated by marrow transplantation. Br J Haematol 1973;24:743-750
CrossRef | Web of Science | Medline19
Kawahara K ,Witherspoon RP ,Storb R . Marrow transplantation for paroxysmal nocturnal hemoglobinuria. Am J Hematol 1992;39:283-288
CrossRef | Web of Science | Medline20
Armitage JO . Bone marrow transplantation. N Engl J Med 1994;330:827-838
Full Text | Web of Science | Medline21
Luzzatto L, Hillmen P. Paroxysmal nocturnal haemoglobinuria. In: Dacie JV, Lewis SM, eds. Practical haematology. 8th ed. Edinburgh, Scotland: Churchill Livingstone, 1995:287-96.
22
Dacie JV ,Lewis SM . Paroxysmal nocturnal haemoglobinuria: clinical manifestations, haematology, and nature of the disease. Ser Haematol 1972;5:3-23
Medline23
Hillmen P ,Hows JM ,Luzzatto L . Two distinct patterns of glycosylphosphatidylinositol (GPI) linked protein deficiency in the red cells of patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 1992;80:399-405
CrossRef | Web of Science | Medline24
Hillmen P ,Bessler M ,Crawford DH ,Luzzatto L . Production and characterization of lymphoblastoid cell lines with the paroxysmal nocturnal hemoglobinuria phenotype. Blood 1993;81:193-199
Web of Science | Medline25
Crosby WH . Paroxysmal nocturnal hemoglobinuria: relation of the clinical manifestations to underlying pathogenic mechanisms. Blood 1953;8:769-812
Web of Science | Medline26
Paroxysmal nocturnal haemoglobinuria. In: Dacie JV. The haemolytic anaemias. London: J&A Churchill, 1954:412-50.
27
Charache S . Prolonged survival in paroxysmal nocturnal hemoglobinuria. Blood 1969;33:877-883
Web of Science | Medline28
Dacie J . Paroxysmal nocturnal haemoglobinuria. Sangre (Barc) 1980;25:890-895
Medline29
Dacie JV ,Gilpin A . Refractory anaemia (Fanconi type). Arch Dis Child 1944;19:155-162
CrossRef | Medline30
Letman H . Possible paroxysmal nocturnal hemoglobinuria with pronounced pancytopenia, reticulocytopenia, and without hemoglobinuria simulating aplastic anemia. Blood 1952;7:842-849
Web of Science | Medline31
Dacie JV ,Lewis SM . Paroxysmal nocturnal haemoglobinuria: variation in clinical severity and association with bone-marrow hypoplasia. Br J Haematol 1961;7:442-457
CrossRef | Web of Science | Medline32
Rotoli B ,Robledo R ,Luzzatto L . Decreased number of circulating BFU-Es in paroxysmal nocturnal hemoglobinuria. Blood 1982;60:157-159
Web of Science | Medline33
Moore JG ,Humphries RK ,Frank MM ,Young N . Characterization of the hematopoietic defect in paroxysmal nocturnal hemoglobinuria. Exp Hematol 1986;14:222-229
Web of Science | Medline34
Kurnick JE ,Robinson WA ,Dickey CA . In vitro granulocytic colony-forming potential of bone marrow from patients with granulocytopenia and aplastic anaemia. Proc Soc Exp Med 1971;137:917-920
Web of Science | Medline35
Tichelli A ,Gratwohl A ,Wursch A ,Nissen C ,Speck B . Late haematological complications in severe aplastic anaemia. Br J Haematol 1988;69:413-418
CrossRef | Web of Science | Medline36
Rotoli B ,Luzzatto L . Paroxysmal nocturnal haemoglobinuria. Semin Hematol 1989;26:201-207
Web of Science | Medline37
Devine DV ,Gluck WL ,Rosse WF ,Weinberg JB . Acute myeloblastic leukemia in paroxysmal nocturnal hemoglobinuria: evidence of evolution from the abnormal paroxysmal nocturnal hemoglobinuria clone. J Clin Invest 1987;79:314-317
CrossRef | Web of Science | Medline38
Longo L ,Bessler M ,Beris P ,Swirsky D ,Luzzatto L . Myelodysplasia in a patient with pre-existing paroxysmal nocturnal haemoglobinuria: a clonal disease originating from within a clonal disease. Br J Haematol 1994;87:401-403
CrossRef | Web of Science | Medline39
van Kamp H ,Smit JW ,van den Berg E ,Halie MR ,Vellenga E . Myelodysplasia following paroxysmal nocturnal haemoglobinuria: evidence for the emergence of a separate clone. Br J Haematol 1994;87:399-400
CrossRef | Web of Science | Medline40
McMullin MF ,Hillmen P ,Jackson J ,Ganly P ,Luzzatto L . Tissue plasminogen activator for hepatic vein thrombosis in paroxysmal nocturnal haemoglobinuria. J Intern Med 1994;235:85-89
CrossRef | Web of Science | Medline
- Citing Articles (173)
Citing Articles
1
Meili Ge, Xingxin Li, Jun Shi, Yingqi Shao, Yizhou Zheng. (2012) Clinical features and prognostic factors of Asian patients with paroxysmal nocturnal hemoglobinuria: results from a single center in China. Annals of Hematology
CrossRef2
Alexander Röth, Ulrich Dührsen. (2011) Treatment of paroxysmal nocturnal hemoglobinuria in the era of eculizumab. European Journal of Haematology 87:6, 473-479
CrossRef3
Kate McKeage. (2011) Eculizumab. Drugs 71:17, 2327-2345
CrossRef4
Malik Goonewardene, Mishkat Shehata. (2011) Anaemia in pregnancy. Best Practice & Research Clinical Obstetrics & Gynaecology
CrossRef5
Hubert Schrezenmeier, Peter Bettelheim, Jens Panse, Jörg Schubert, Britta Höchsmann, Alexander Röth, Thomas Nebe. (2011) Empfehlungen zur Diagnostik der Paroxysmalen nächtlichen Hämoglobinurie: deutsch – österreichischer Konsensus/Recommendations for the diagnosis of paroxysmal nocturnal hemoglobinuria: a German-Austrian consensus. LaboratoriumsMedizin 35:6, 315-327
CrossRef6
S.T.A. van Bijnen, W.L. van Heerde, P. Muus. (2011) Mechanisms and Clinical Implications of Thrombosis in Paroxysmal Nocturnal Hemoglobinuria. Journal of Thrombosis and Haemostasisno-no
CrossRef7
2011. Glycosylation in Health and Disease. .
CrossRef8
B. Höchsmann, R. Leichtle, I. von Zabern, S. Kaiser, W. A. Flegel, H. Schrezenmeier. (2011) Paroxysmal nocturnal haemoglobinuria treatment with eculizumab is associated with a positive direct antiglobulin test. Vox Sanguinisno-no
CrossRef9
Britta Höchsmann, Markus Rojewski, Hubert Schrezenmeier. (2011) Paroxysmal nocturnal hemoglobinuria (PNH): higher sensitivity and validity in diagnosis and serial monitoring by flow cytometric analysis of reticulocytes. Annals of Hematology 90:8, 887-899
CrossRef10
Jeffrey J. Pu, Galina Mukhina, Hao Wang, William J. Savage, Robert A. Brodsky. (2011) Natural history of paroxysmal nocturnal hemoglobinuria clones in patients presenting as aplastic anemia. European Journal of Haematology 87:1, 37-45
CrossRef11
R. J. Kelly, A. Hill, L. M. Arnold, G. L. Brooksbank, S. J. Richards, M. Cullen, L. D. Mitchell, D. R. Cohen, W. M. Gregory, P. Hillmen. (2011) Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood 117:25, 6786-6792
CrossRef12
Alexander Röth, Christina Hock, Anna Konik, Sandra Christoph, Ulrich Dührsen. (2011) Chronic treatment of paroxysmal nocturnal hemoglobinuria patients with eculizumab: safety, efficacy, and unexpected laboratory phenomena. International Journal of Hematology 93:6, 704-714
CrossRef13
Jacek Nowak, Renata Mika-Witkowska, Ewa Mendek-Czajkowska, Marta Rogatko-Koroś, Elżbieta Graczyk-Pol, Hanna Pyl, Aneta Klimczak, Małgorzata Wójcik, Monika Prochorec-Sobieszek, Renata Maryniak, Barbara Żupańska. (2011) The Patterns of MHC Association in Aplastic and Non-aplastic Paroxysmal Nocturnal Hemoglobinuria. Archivum Immunologiae et Therapiae Experimentalis 59:3, 231-238
CrossRef14
Jeffrey J. Pu, Robert A. Brodsky. (2011) Paroxysmal Nocturnal Hemoglobinuria from Bench to Bedside. Clinical and Translational Science 4:3, 219-224
CrossRef15
Lucio Luzzatto, Giacomo Gianfaldoni, Rosario Notaro. (2011) Management of Paroxysmal Nocturnal Haemoglobinuria: a personal view. British Journal of Haematology 153:6, 709-720
CrossRef16
Montserrat López Rubio, Marta Morado, Ana Gaya, Dora Alonso Rosa, Emilio Ojeda, Juan Antonio Muñoz, Begoña Pérez de Mendiguren, María Dolores Monteagudo, José María Durán, Rosa María Fisac, Damián Moreno, Ana María Villegas. (2011) Tratamiento de la hemoglobinuria paroxística nocturna con eculizumab: experiencia en España. Medicina Clínica 137:1, 8-13
CrossRef17
R. E. G. Schutgens, K. A. B. M. Pruissen-Peeters, P. Muus. (2011) A cascade of thromboembolic processes in a patient with paroxysmal nocturnal haemoglobinuria terminated by treatment with eculizumab. Thrombosis and Haemostasis 106:2, 383-385
CrossRef18
Yuzuru Kanakura, Kazuma Ohyashiki, Tsutomu Shichishima, Shinichiro Okamoto, Kiyoshi Ando, Haruhiko Ninomiya, Tatsuya Kawaguchi, Shinji Nakao, Hideki Nakakuma, Jun-ichi Nishimura, Taroh Kinoshita, Camille L. Bedrosian, Marye Ellen Valentine, Gus Khursigara, Keiya Ozawa, Mitsuhiro Omine. (2011) Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: the AEGIS Clinical Trial. International Journal of Hematology 93:1, 36-46
CrossRef19
Stefano Pulini, Ludovica Marando, Annalisa Natale, Caterina Pascariello, Virginia Catinella, Luigi Del Vecchio, Antonio M. Risitano, Giuseppe Fioritoni. (2011) Paroxysmal Nocturnal Hemoglobinuria after Autologous Stem Cell Transplantation: Extinction of the Clone during Treatment with Eculizumab – Pathophysiological Implications of a Unique Clinical Case. Acta Haematologica 126:2, 103-109
CrossRef20
Philip Lanzkowsky. 2011. Red Cell Membrane and Enzyme Defects. , 168-199.
CrossRef21
Kevin J. Curran, Nancy A. Kernan, Susan E. Prockop, Andromachi Scaradavou, Trudy N. Small, Rachel Kobos, Hugo Castro-Malaspina, David Araten, Donna DiMichele, Richard J. O'Reilly, Farid Boulad. (2011) Paroxysmal nocturnal hemoglobinuria in pediatric patients. Pediatric Blood & Cancern/a-n/a
CrossRef22
Nicoletta Riva, Elena Rancan, Walter Ageno, Francesco Dentali. (2010) Unmet clinical needs in the management of patients with splanchnic vein thrombosis. Internal and Emergency Medicine 5:6, 459-461
CrossRef23
A. Grigg, M. Brown, J. Szer. (2010) Durable resolution of recurrent microvascular small bowel ischaemia and severe abdominal pain by eculizumab in paroxysmal nocturnal haemoglobinuria. Internal Medicine Journal 40:11, 794-795
CrossRef24
Peter Hillmen. 2010. Paroxysmal Nocturnal Haemoglobinuria. , 176-185.
CrossRef25
Alon Grossman, Hefziba Green, Anat Gafter-Gvili, Yael Zimra, Esther Rabizadeh, Ilan Krause. (2010) Co-existence of paroxysmal nocturnal hemoglobinuria and antiphospholipid syndrome—A role for complement activation. Leukemia Research 34:9, e251-e253
CrossRef26
Saleh Rachidi, Khaled M. Musallam, Ali T. Taher. (2010) A closer look at paroxysmal nocturnal hemoglobinuria. European Journal of Internal Medicine 21:4, 260-267
CrossRef27
Peter Hillmen, Modupe Elebute, Richard Kelly, Alvaro Urbano-Ispizua, Anita Hill, Russell P. Rother, Gus Khursigara, Chieh-Lin Fu, Mitsuhiro Omine, Paul Browne, Wendell Rosse. (2010) Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. American Journal of Hematology 85:8, 553-559
CrossRef28
Antonio Guasch. (2010) Improving renal outcomes in chronic anemia: Learning from paroxysmal nocturnal hemoglobinuria. American Journal of Hematology 85:8, 551-552
CrossRef29
Joana Torres, Bénédicte De Vroey, Marie-Pierre Noël, Bertrand Notteghem, Jean-Frédéric Colombel. (2010) Recurrent small bowel ischemia in a patient with paroxysmal nocturnal hemoglobinuria. Nature Reviews Gastroenterology & Hepatology 7:7, 410-414
CrossRef30
Juan Xiao, Bing Han, Yong-ji Wu, Yu-ping Zhong, Wan-ling Sun. (2010) Ex vivo expansion and long-term hematopoietic reconstitution ability of sorted CD34+CD59+ cells from patients with paroxysmal nocturnal hemoglobinuria. International Journal of Hematology 92:1, 58-67
CrossRef31
Francesco Dragoni, Anna Paola Iori, Patrizia Pignoloni, Chiara Minotti, Flavia Chiarotti, Maria Gabriella Mazzucconi, Andrea Mengarelli, William Arcese, Robin Foà, Giuseppe Avvisati. (2010) Thrombophilic screening in patients with paroxysmal nocturnal haemoglobinuria: a pilot study. British Journal of Haematologyno-no
CrossRef32
Richard Kelly, Louise Arnold, Stephen Richards, Anita Hill, Charlotte Bomken, John Hanley, Andrew Loughney, Jon Beauchamp, Gus Khursigara, Russell P. Rother, Elizabeth Chalmers, Andrew Fyfe, Edward Fitzsimons, Ryotaro Nakamura, Anna Gaya, Antonio M. Risitano, Jörg Schubert, Derek Norfolk, Nigel Simpson, Peter Hillmen. (2010) The management of pregnancy in paroxysmal nocturnal haemoglobinuria on long term eculizumab. British Journal of Haematology 149:3, 446-450
CrossRef33
Alexey V. Danilov, Robert A. Brodsky, Sabrina Craigo, Hedy Smith, Kenneth B. Miller. (2010) Managing a pregnant patient with paroxysmal nocturnal hemoglobinuria in the era of eculizumab. Leukemia Research 34:5, 566-571
CrossRef34
Anita Hill, Russell P. Rother, Xunde Wang, Sidney M. Morris, Jr, Kerry Quinn-Senger, Richard Kelly, Stephen J. Richards, Monica Bessler, Leonard Bell, Peter Hillmen, Mark T. Gladwin. (2010) Effect of eculizumab on haemolysis-associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology 149:3, 414-425
CrossRef35
Ilene C. Weitz. (2010) Thrombosis in Paroxysmal Nocturnal Hemoglobinuria – insights into the role of complement in thrombosis. Thrombosis Research 125, S106-S107
CrossRef36
Maria J. Marcaida, Inés G. Muñoz, Francisco J. Blanco, Jesús Prieto, Guillermo Montoya. (2010) Homing endonucleases: from basics to therapeutic applications. Cellular and Molecular Life Sciences 67:5, 727-748
CrossRef37
Michael J. Borowitz, Fiona E. Craig, Joseph A. DiGiuseppe, Andrea J. Illingworth, Wendell Rosse, D. Robert Sutherland, Carl T. Wittwer, Stephen J. Richards. (2010) Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry. Cytometry Part B: Clinical Cytometryn/a-n/a
CrossRef38
David Dingli, Jorge M. Pacheco. (2010) Modeling the architecture and dynamics of hematopoiesis. Wiley Interdisciplinary Reviews: Systems Biology and Medicinen/a-n/a
CrossRef39
Jin Seok Kim, Jong Wook Lee, Byoung Kook Kim, Je-Hwan Lee, Jooseop Chung. (2010) The use of the complement inhibitor eculizumab (Soliris®) for treating Korean patients with paroxysmal nocturnal hemoglobinuria. The Korean Journal of Hematology 45:4, 269
CrossRef40
Elisabeth Georgiou, Mark Layton, Anastasios Karadimitris. (2009) Inherited GPI deficiency: A disorder of histone hypoacetylation. Birth Defects Research Part C: Embryo Today: Reviews 87:4, 327-334
CrossRef41
Chiharu Sugimori, Kanako Mochizuki, Zhirong Qi, Naomi Sugimori, Ken Ishiyama, Yukio Kondo, Hirohito Yamazaki, Akiyoshi Takami, Hirokazu Okumura, Shinji Nakao. (2009) Origin and fate of blood cells deficient in glycosylphosphatidylinositol-anchored protein among patients with bone marrow failure. British Journal of Haematology 147:1, 102-112
CrossRef42
Ashkan Emadi, Robert A. Brodsky. (2009) Successful discontinuation of anticoagulation following eculizumab administration in paroxysmal nocturnal hemoglobinuria. American Journal of Hematology 84:10, 699-701
CrossRef43
Jildou Hoekstra, Frank W.G. Leebeek, Aurelie Plessier, Sebastian Raffa, Sarwa Darwish Murad, Jörg Heller, Antoine Hadengue, Carine Chagneau, Elwyn Elias, Massimo Primignani, Juan-Carlos Garcia-Pagan, Dominique C. Valla, Harry L.A. Janssen. (2009) Paroxysmal nocturnal hemoglobinuria in Budd-Chiari Syndrome: Findings from a cohort study. Journal of Hepatology 51:4, 696-706
CrossRef44
Paul Cullen, Susanne Adam, Brigitte Kaiser, Michael Neumaier. (2009) Diagnosing thrombophilia today with particular reference to genetic factors and the antiphospholipid antibody syndrome 1. LaboratoriumsMedizin 33:5, ---
CrossRef45
Paul Cullen, Susanne Adam, Brigitte Kaiser, Michael Neumaier. (2009) Status der Thrombophilie-Diagnostik unter besonderer Berücksichtigung molekulargenetischer Aspekte / Diagnosing thrombophilia with particular reference to genetic factors. LaboratoriumsMedizin 33:5, 283-292
CrossRef46
Ramon Tiu, Hussam Yacoub, Jaroslaw Maciejewski, Cathy A. Sila. (2009) Recurrent Ischemic Stroke in Paroxysmal Nocturnal Hemoglobinuria: Paroxysmal Nocturnal Hemoglobinuria or Missed Patent Foramen Ovale?. Journal of Stroke and Cerebrovascular Diseases 18:5, 409-410
CrossRef47
Christopher S. Kleeman, Timothy P. Maroney, David A. Sass. (2009) Bleeding Rectal Varices: Trouble Upstream?. Gastroenterology 137:2, 433-746
CrossRef48
R. A. Brodsky. (2009) How I treat paroxysmal nocturnal hemoglobinuria. Blood 113:26, 6522-6527
CrossRef49
Nelson A. Matos-Fernandez, Yasser R. Abou Mourad, William Caceres, Mohamed A. Kharfan-Dabaja. (2009) Current Status of Allogeneic Hematopoietic Stem Cell Transplantation for Paroxysmal Nocturnal Hemoglobinuria. Biology of Blood and Marrow Transplantation 15:6, 656-661
CrossRef50
Alexey V. Danilov, Hedy Smith, Sabrina Craigo, Dianne M. Feeney, Valerie Relias, Kenneth B. Miller. (2009) Paroxysmal nocturnal hemoglobinuria (PNH) and pregnancy in the era of eculizumab. Leukemia Research 33:6, e4-e5
CrossRef51
Andrew L. Singer, Jamye E. Locke, Zoe A. Stewart, Bonnie E. Lonze, James P. Hamilton, Jennifer R. Scudiere, Robert A. Anders, Russell P. Rother, Robert A. Brodsky, Andrew M. Cameron. (2009) Successful liver transplantation for Budd-Chiari syndrome in a patient with paroxysmal nocturnal hemoglobinuria treated with the anti-complement antibody eculizumab. Liver Transplantation 15:5, 540-543
CrossRef52
Laurie D. DeLeve, Dominique-Charles Valla, Guadalupe Garcia-Tsao. (2009) Vascular disorders of the liver. Hepatology 49:5, 1729-1764
CrossRef53
A. M. Risitano, R. Notaro, L. Marando, B. Serio, D. Ranaldi, E. Seneca, P. Ricci, F. Alfinito, A. Camera, G. Gianfaldoni, A. Amendola, C. Boschetti, E. Di Bona, G. Fratellanza, F. Barbano, F. Rodeghiero, A. Zanella, A. P. Iori, C. Selleri, L. Luzzatto, B. Rotoli. (2009) Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. Blood 113:17, 4094-4100
CrossRef54
Charles J. Parker. (2009) Bone Marrow Failure Syndromes: Paroxysmal Nocturnal Hemoglobinuria. Hematology/Oncology Clinics of North America 23:2, 333-346
CrossRef55
Hubert Schrezenmeier, Britta Höchsmann. (2009) Eculizumab opens a new era of treatment for paroxysmal nocturnal hemoglobinuria. Expert Review of Hematology 2:1, 7-16
CrossRef56
Antonella Tufano, Nicola Macarone Palmieri, Ernesto Cimino, Fiorella Alfinito, Anna Maria Cerbone. (2009) Budd-Chiari syndrome in a paroxysmal nocturnal hemoglobinuria patient with previous cerebral venous thrombosis. Internal and Emergency Medicine 4:1, 75-77
CrossRef57
Charles Parker. (2009) Eculizumab for paroxysmal nocturnal haemoglobinuria. The Lancet 373:9665, 759-767
CrossRef58
Neal S. Young, Gabrielle Meyers, Hubert Schrezenmeier, Peter Hillmen, Anita Hill. (2009) The Management of Paroxysmal Nocturnal Hemoglobinuria: Recent Advances in Diagnosis and Treatment and New Hope for Patients. Seminars in Hematology 46, S1-S16
CrossRef59
Stephen J. Richards, Liam Whitby, Matthew J. Cullen, Anita J. Dickinson, Viv Granger, John T. Reilly, Peter Hillmen, David Barnett. (2009) Development and evaluation of a stabilized whole-blood preparation as a process control material for screening of paroxysmal nocturnal hemoglobinuria by flow cytometry. Cytometry Part B: Clinical Cytometry 76B:1, 47-55
CrossRef60
Elaine M. Sloand, Loretta Pfannes, Phillip Scheinberg, Kenneth More, Colin O. Wu, McDonald Horne, Neal S. Young. (2008) Increased soluble urokinase plasminogen activator receptor (suPAR) is associated with thrombosis and inhibition of plasmin generation in paroxysmal nocturnal hemoglobinuria (PNH) patients. Experimental Hematology 36:12, 1616-1624
CrossRef61
D. Dingli, L. Luzzatto, J. M. Pacheco. (2008) Neutral evolution in paroxysmal nocturnal hemoglobinuria. Proceedings of the National Academy of Sciences 105:47, 18496-18500
CrossRef62
L. Geffray. (2008) Hémoglobinurie paroxystique nocturne. La Revue de Médecine Interne 29:11, 957-961
CrossRef63
Pilar M. Hernández-Campo, Julia Almeida, Alberto Orfao. (2008) Hemoglobinuria paroxística nocturna. Medicina Clínica 131:16, 617-630
CrossRef64
R. P. de Latour, J. Y. Mary, C. Salanoubat, L. Terriou, G. Etienne, M. Mohty, S. Roth, S. de Guibert, S. Maury, J. Y. Cahn, G. Socie, . (2008) Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories. Blood 112:8, 3099-3106
CrossRef65
Francesca Vinchi, Stefania Gastaldi, Lorenzo Silengo, Fiorella Altruda, Emanuela Tolosano. (2008) Hemopexin Prevents Endothelial Damage and Liver Congestion in a Mouse Model of Heme Overload. The American Journal of Pathology 173:1, 289-299
CrossRef66
R. A. Brodsky, N. S. Young, E. Antonioli, A. M. Risitano, H. Schrezenmeier, J. Schubert, A. Gaya, L. Coyle, C. de Castro, C.-L. Fu, J. P. Maciejewski, M. Bessler, H.-A. Kroon, R. P. Rother, P. Hillmen. (2008) Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood 111:4, 1840-1847
CrossRef67
Anastasios Karadimitris, Rosario Notaro, Gunther Koehne, Irene A. G. Roberts, Lucio Luzzatto. (2008) PNH cells are as sensitive to T-cell-mediated lysis as their normal counterparts: implications for the pathogenesis of paroxysmal nocturnal haemoglobinuria. British Journal of Haematology 111:4, 1158
CrossRef68
Lisa Charneski, Priti N Patel. (2008) Eculizumab in Paroxysmal Nocturnal Haemoglobinuria. Drugs 68:10, 1341-1346
CrossRef69
M. Bessler, J. Hiken. (2008) The Pathophysiology of Disease in Patients with Paroxysmal Nocturnal Hemoglobinuria. Hematology 2008:1, 104-110
CrossRef70
P. Hillmen. (2008) The Role of Complement Inhibition in PNH. Hematology 2008:1, 116-123
CrossRef71
Gabriela M. Baerlocher, Elaine M. Sloand, Neal S. Young, Peter M. Lansdorp. (2007) Telomere length in paroxysmal nocturnal hemoglobinuria correlates with clone size. Experimental Hematology 35:12, 1777-1781
CrossRef72
P. Hillmen, P. Muus, U. Duhrsen, A. M. Risitano, J. Schubert, L. Luzzatto, H. Schrezenmeier, J. Szer, R. A. Brodsky, A. Hill, G. Socie, M. Bessler, S. A. Rollins, L. Bell, R. P. Rother, N. S. Young. (2007) Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood 110:12, 4123-4128
CrossRef73
P CARLI, B GRAFFIN, O GISSEROT, C LANDAIS, J DEJAUREGUIBERRY. (2007) Maladie thromboembolique récidivante après splénectomie pour stomatocytose héréditaire. La Revue de Médecine Interne 28:12, 879-881
CrossRef74
Shunya Shindo, Shinya Motohashi, Shigeaki Kaga, Hidenori Inoue, Masahiko Matsumoto, Hiroo Shindo. (2007) Paroxysmal nocturnal hemoglobinuria: complete resolution of an occluding inferior vena caval thrombus. Abdominal Imaging 32:6, 754-757
CrossRef75
Charissa Y. Chang, Ashwani K. Singal, Sri V. Ganeshan, Thomas D. Schiano, Robert Lookstein, Sukru Emre. (2007) Use of splenic artery embolization to relieve tense ascites following liver transplantation in a patient with paroxysmal nocturnal hemoglobinuria. Liver Transplantation 13:11, 1532-1537
CrossRef76
Russell P Rother, Scott A Rollins, Christopher F Mojcik, Robert A Brodsky, Leonard Bell. (2007) Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nature Biotechnology 25:11, 1256-1264
CrossRef77
Stephen J. Richards, Anita Hill, Peter Hillmen. (2007) Recent advances in the diagnosis, monitoring, and management of patients with paroxysmal nocturnal hemoglobinuria. Cytometry Part B: Clinical Cytometry 72B:5, 291-298
CrossRef78
Sapandeep K. Singh, Dalia G. Galicia, David P. Huston. (2007) Clinical trials report. Current Allergy and Asthma Reports 7:5, 319-322
CrossRef79
Charles J. Parker, Santwana Kar, Peter Kirkpatrick. (2007) Eculizumab. Nature Reviews Drug Discovery 6:7, 515-516
CrossRef80
L. Gargiulo, S. Lastraioli, G. Cerruti, M. Serra, F. Loiacono, S. Zupo, L. Luzzatto, R. Notaro. (2007) Highly homologous T-cell receptor beta sequences support a common target for autoreactive T cells in most patients with paroxysmal nocturnal hemoglobinuria. Blood 109:11, 5036-5042
CrossRef81
Anita Hill, Stephen J. Richards, Peter Hillmen. (2007) Recent developments in the understanding and management of paroxysmal nocturnal haemoglobinuria. British Journal of Haematology 137:3, 181-192
CrossRef82
D. Robert Sutherland, Nancy Kuek, Jeff Davidson, David Barth, Hong Chang, Erik Yeo, Sylvia Bamford, Ian Chin-Yee, Michael Keeney. (2007) Diagnosing PNH with FLAER and multiparameter flow cytometry. Cytometry Part B: Clinical Cytometry 72B:3, 167-177
CrossRef83
Almeida, Antonio M., Murakami, Yoshiko, Baker, Alastair, Maeda, Yusuke, Roberts, Irene A.G., Kinoshita, Taroh, Layton, D. Mark, Karadimitris, Anastasios, . (2007) Targeted Therapy for Inherited GPI Deficiency. New England Journal of Medicine 356:16, 1641-1647
Full Text84
Charles J. Parker. (2007) The pathophysiology of paroxysmal nocturnal hemoglobinuria. Experimental Hematology 35:4, 523-533
CrossRef85
Kazuhiko Ikeda, Tsutomu Shichishima, Masaki Yasukawa, Akiko Nakamura-Shichishima, Hideyoshi Noji, Kazuko Akutsu, Kazuoki Osumi, Yukio Maruyama. (2007) The role of Wilms' tumor gene peptide–specific cytotoxic T lymphocytes in immunologic selection of a paroxysmal nocturnal hemoglobinuria clone. Experimental Hematology 35:4, 618-626
CrossRef86
P. D. ZIAKAS, L. S. POULOU, G. I. ROKAS, D. BARTZOUDIS, M. VOULGARELIS. (2007) Thrombosis in paroxysmal nocturnal hemoglobinuria: sites, risks, outcome. An overview. Journal of Thrombosis and Haemostasis 5:3, 642-645
CrossRef87
Carmela Cacciapuoti, Giuseppe Terrazzano, Lucia Barone, Michela Sica, Cristina Becchimanzi, Bruno Rotoli, Giuseppina Ruggiero, Fiorella Alfinito. (2007) Glycosyl-phosphatidyl-inositol-defective granulocytes from paroxysmal nocturnal haemoglobinuria patients show increased bacterial ingestion but reduced respiratory burst induction. American Journal of Hematology 82:2, 98-107
CrossRef88
Alejandro Ruiz-Argüelles, Luis Llorente. (2007) The role of complement regulatory proteins (CD55 and CD59) in the pathogenesis of autoimmune hemocytopenias. Autoimmunity Reviews 6:3, 155-161
CrossRef89
John A. Heit. 2007. Thrombophilia: Clinical and Laboratory Assessment and Management. , 211-244.
CrossRef90
T H Brümmendorf, S Balabanov. (2006) Telomere length dynamics in normal hematopoiesis and in disease states characterized by increased stem cell turnover. Leukemia 20:10, 1706-1716
CrossRef91
Wanchai Wanachiwanawin, Uamporn Siripanyaphinyo, Nattawan Piyawattanasakul, Taroh Kinoshita. (2006) A cohort study of the nature of paroxysmal nocturnal hemoglobinuria clones and PIG-A mutations in patients with aplastic anemia. European Journal of Haematology 76:6, 502-509
CrossRef92
Ramaprasad Srinivasan, Yoshiyuki Takahashi, J. Philip McCoy, Igor Espinoza-Delgado, Colleen Dorrance, Takehito Igarashi, Andreas Lundqvist, A. John Barrett, Neal S Young, Nancy Geller, Richard W. Childs. (2006) Overcoming graft rejection in heavily transfused and allo-immunised patients with bone marrow failure syndromes using fludarabine-based haematopoietic cell transplantation. British Journal of Haematology 133:3, 305-314
CrossRef93
Keith K. Lau, Bettina H. Ault. (2006) A child with recurrent episodes of dark urine: answer. Pediatric Nephrology 21:4, 472-474
CrossRef94
George P. Kuo, Robert A. Brodsky, Hyun S. Kim. (2006) Catheter-directed Thrombolysis and Thrombectomy for the Budd-Chiari Syndrome in Paroxysmal Nocturnal Hemoglobinuria in Three Patients. Journal of Vascular and Interventional Radiology 17:2, 383-387
CrossRef95
Dong-Jun Shin, Duck Cho, Young Ran Kim, Joon Haeng Rhee, Hyon E. Choy, Je-Jung Lee, Yeongjin Hong. (2006) Diagnosis of Paroxysmal Nocturnal Hemoglobinuria by Fluorescent <i>Clostridium septicum</i> Alpha Toxin. Journal of Molecular Microbiology and Biotechnology 11:1-2, 20-27
CrossRef96
Robert A. Brodsky, Rong Hu. (2006) PIG-A mutations in paroxysmal nocturnal hemoglobinuria and in normal hematopoiesis. Leukemia & Lymphoma 47:7, 1215-1221
CrossRef97
Takeshi Nara, Sachiyo Kimori, Hiroshi Nakamichi, Yoshihiro Ikeda, Teruaki Akaogi, Mizuho Kurita, Ryouzou Okuda, Norito Katoh, Saburou Kishimoto. (2005) Extensive purpura in a patient with paroxysmal nocturnal hemoglobinuria. Journal of the American Academy of Dermatology 53:6, 1090-1092
CrossRef98
Mitsuhiro Omine, Taroh Kinoshita, Hideki Nakakuma, Jaroslaw P. Maciejewski, Charles J. Parker, Gérard Socié. (2005) Paroxysmal Nocturnal Hemoglobinuria. International Journal of Hematology 82:5, 417-421
CrossRef99
H. Audebert, J. Planck, M. Eisenburg, H. Schrezenmeier, R. L. Haberl. (2005) Cerebral Ischemic Infarction in Paroxysmal Nocturnal Hemoglobinuria. Journal of Neurology 252:11, 1379-1386
CrossRef100
C. Diskin. (2005) Paroxysmal Nocturnal Hemoglobinuria After Chloramphenicol Therapy. Mayo Clinic Proceedings 80:10, 1392-1394
CrossRef101
Philip T. Murphy, Michael Fay, John Quinn, J. Rory O’Donnell. (2005) Remission of transfusion-dependent myelodysplastic syndrome in association with respiratory tract infection. Annals of Hematology 84:9, 614-615
CrossRef102
Mitchell Lewis. (2005) Sir John Dacie MD, FRS, FRCP, FRCPath. British Journal of Haematology 130:6, 834-844
CrossRef103
Ernesto P. Molmenti, Dorry L. Segev, Aravind Arepally, Jenny Hong, Paul J. Thuluvath, Rudra Rai, Andrew S. Klein. (2005) The Utility of TIPS in the Management of Budd-Chiari Syndrome. Annals of Surgery 241:6, 978-983
CrossRef104
Stam, Jan, . (2005) Thrombosis of the Cerebral Veins and Sinuses. New England Journal of Medicine 352:17, 1791-1798
Full Text105
Julien Vergniol, David Laharie, Jacques Drouillard, Gabriel Etienne, Arnaud Pigneux, Aur??lie Plessier, Patrice Couzigou, Victor de L??dinghen. (2005) Paroxysmal nocturnal hemoglobinuria and Budd???Chiari syndrome: therapeutic challenge with bone marrow transplantation, transjugular intrahepatic portosystemic shunt, and vena cava stent. European Journal of Gastroenterology & Hepatology 17:4, 453-456
CrossRef106
Dong-Jun Shin, Je-Jung Lee, Hyon E. Choy, Yeongjin Hong. (2004) Generation and characterization of Clostridium septicum α toxin mutants and their use in diagnosing paroxysmal nocturnal hemoglobinuria. Biochemical and Biophysical Research Communications 324:2, 753-760
CrossRef107
Carla Boschetti, Elisa Fermo, Paola Bianchi, Cristina Vercellati, Fiorenza Barraco, Alberto Zanella. (2004) Clinical and molecular aspects of 23 patients affected by paroxysmal nocturnal hemoglobinuria. American Journal of Hematology 77:1, 36-44
CrossRef108
Victor M. Moyo, Galina L. Mukhina, Elizabeth S. Garrett, Robert A. Brodsky. (2004) Natural history of paroxysmal nocturnal haemoglobinuria using modern diagnostic assays. British Journal of Haematology 126:1, 133-138
CrossRef109
Jun-Ichi Nishimura, Yuzuru Kanakura, Russell E. Ware, Tsutomu Shichishima, Hideki Nakakuma, Haruhiko Ninomiya, Carlos M. Decastro, Sharon Hall, Akihisa Kanamaru, Keith M. Sullivan, Hideaki Mizoguchi, Mitsuhiro Omine, Taroh Kinoshita, Wendell F. Rosse. (2004) Clinical Course and Flow Cytometric Analysis of Paroxysmal Nocturnal Hemoglobinuria in the United States and Japan. Medicine 83:3, 193-207
CrossRef110
Serelina Coluzzi, Mauro Biffoni, Daniela Pasqualetti, Maria Paola Perrone, Stefania Vaglio, Hassan Rahimi, Maria Cristina Arista, Luca Laurenti, Raffaella Cerretti, Gabriella Girelli. (2004) Production of interferon-gamma by lymphocytes from paroxysmal nocturnal haemoglobinuria patients: relationship with clinical status. British Journal of Haematology 124:5, 685-690
CrossRef111
Hillmen, Peter, Hall, Claire, Marsh, Judith C.W., Elebute, Modupe, Bombara, Michael P., Petro, Beth E., Cullen, Matthew J., Richards, Stephen J., Rollins, Scott A., Mojcik, Christopher F., Rother, Russell P., . (2004) Effect of Eculizumab on Hemolysis and Transfusion Requirements in Patients with Paroxysmal Nocturnal Hemoglobinuria. New England Journal of Medicine 350:6, 552-559
Full Text112
SP Higgins, LP McMahon, SP Brennecke. (2004) Paroxysmal nocturnal haemoglobinuria in pregnancy—not to be confused with pre-eclampsia or HELLP syndrome. Case report and literature review. Journal of Obstetrics & Gynaecology 24:1, 83-85
CrossRef113
Matthias J. Bahr, Jorg Schubert, Jorg S. Bleck, Uwe J.F. Tietge, Bita Boozari, Reinhold E. Schmidt, Jurgen Klempnauer, Christian P. Strassburg, Michael P. Manns. (2003) Recurrence of Budd-Chiari syndrome after liver transplantation in paroxysmal nocturnal hemoglobinuria. Transplant International 16:12, 890-894
CrossRef114
J. C. W. Marsh, M. O. Elebute. (2003) Stem cells in paroxysmal nocturnal haemoglobinuria and aplastic anaemia: increasing evidence for overlap of haemopoietic defect. Transfusion Medicine 13:6, 377-386
CrossRef115
Modupe O. Elebute, Sian Rizzo, Jennifer A. Tooze, Judith C. W. Marsh, Edward C. Gordon-Smith, Frances. M. Gibson. (2003) Evaluation of the haemopoietic reservoir in de novo haemolytic paroxysmal nocturnal haemoglobinuria. British Journal of Haematology 123:3, 552-560
CrossRef116
U Hegenbart, D Niederwieser, S Forman, E Holler, S Leiblein, L Johnston, W Pönisch, E Epner, R Witherspoon, K Blume, R Storb. (2003) Hematopoietic cell transplantation from related and unrelated donors after minimal conditioning as a curative treatment modality for severe paroxysmal nocturnal hemoglobinuria. Biology of Blood and Marrow Transplantation 9:11, 689-697
CrossRef117
Martin Grünewald, Annelie Siegemund, Anja Grünewald, Anke Schmid, Mario Koksch, Christine Schöpflin, Stefanie Schauer, Martin Griesshammer. (2003) Plasmatic coagulation and fibrinolytic system alterations in PNH. Blood Coagulation & Fibrinolysis 14:7, 685-695
CrossRef118
T. Nebe, J. Schubert, K. Gutensohn, H. Schrezenmeier. (2003) Flow Cytometric Analysis of GPI-deficient Cells for the Diagnosis of Paroxysmal Nocturnal Hemoglobinuria (PNH)/Durchflußzytometrische Analyse GPI-defizienter Zellen zur Diagnose der paroxysmalen nächtlichen Hämoglobinurie (PNH). LaboratoriumsMedizin 27:7-8, 257-265
CrossRef119
Jae-Lyun Lee, Je-Hwan Lee, Jung-Hee Lee, Seong-Jun Choi, Shin Kim, Miee Seol, Young-Shin Lee, Hyun-Sook Chi, Chan-Jeoung Park, Woo-Kun Kim, Jung-Shin Lee, Kyoo-Hyung Lee. (2003) Allogeneic hematopoietic cell transplantation for paroxysmal nocturnal hemoglobinuria. European Journal of Haematology 71:2, 114-118
CrossRef120
Val??rie Biousse. (2003) The Coagulation System. Journal of Neuro-Ophthalmology 23:1, 50-62
CrossRef121
Wendell F. Rosse, Junichi Nishimura. (2003) Clinical Manifestations of Paroxysmal Nocturnal Hemoglobinuria: Present State and Future Problems. International Journal of Hematology 77:2, 113-120
CrossRef122
Hideki Nakakuma, Tatsuya Kawaguchi. (2003) Pathogenesis of Selective Expansion of PNH Clones. International Journal of Hematology 77:2, 121-124
CrossRef123
Gabrielle Meyers, Charles J. Parker. (2003) Management Issues in Paroxysmal Nocturnal Hemoglobinuria. International Journal of Hematology 77:2, 125-132
CrossRef124
C. Huehn, M. Righini, M. Starobinski, A. Angelillo-Scherrer, P. De Moerloose. (2003) Are patients with paroxysmal nocturnal hemoglobinuria at risk for heparin-induced thrombocytopenia?. Journal of Thrombosis and Haemostasis 1:2, 389-390
CrossRef125
Antonio M Risitano, Karel Holada, Guibin Chen, Jan Simak, Jaroslav G Vostal, Neal S Young, Jaroslaw P Maciejewski. (2003) CD34+ cells from paroxysmal nocturnal hemoglobinuria (PNH) patients are deficient in surface expression of cellular prion protein (PrP c). Experimental Hematology 31:1, 65-72
CrossRef126
Line Bjørge, Peter Ernst, Kjell O. Haram. (2003) Paroxysmal nocturnal hemoglobinuria in pregnancy. Acta Obstetricia et Gynecologica Scandinavica 82:12, 1067-1071
CrossRef127
Howard A Liebman, Donald I Feinstein. (2003) Thrombosis in patients with paroxysmal noctural hemoglobinuria is associated with markedly elevated plasma levels of leukocyte-derived tissue factor. Thrombosis Research 111:4-5, 235-238
CrossRef128
Akihito Fujimi, Takuya Matsunaga, Katsuhisa Kogawa, Takayuki Ohnuma, Naoki Takahira, Tomoyuki Abe, Keisuke Kitaoka, Takahiro Kogawa, Ikuta Tanaka, Kazuhiro Morii, Takeshi Terui, Sumio Sakamaki, Junji Kato, Toshiro Kura, Takeshi Maeda, Yoshiro Niitsu. (2002) A patient with paroxysmal nocturnal haemoglobinuria in whom granulocyte colony-stimulating factor administration resulted in improvement of recurrent enterocolitis and its associated haemolytic attacks. British Journal of Haematology 119:3, 858-862
CrossRef129
Jun-ichi Nishimura, Russell E. Ware, Angela Burnette, Andrew L. Pendleton, Kiyoshi Kitano, Toshiyuki Hirota, Takashi Machii, Teruo Kitani, Clay A. Smith, Wendell F. Rosse. (2002) The Hematopoietic Defect in PNH Is Not Due to Defective Stroma, but Is Due to Defective Progenitor Cells. Blood Cells, Molecules, and Diseases 29:2, 159-167
CrossRef130
Christian Flotho, Brigitte Strahm, Udo Kontny, Ulrich Duffner, Anke M. J. Peters, Wolfgang Dupuis, Charlotte M. Niemeyer. (2002) Stem cell transplantation for paroxysmal nocturnal haemoglobinuria in childhood. British Journal of Haematology 118:1, 124-127
CrossRef131
VITTORIO ROSTI. (2002) Murine Models of Paroxysmal Nocturnal Hemoglobinuria. Annals of the New York Academy of Sciences 963:1, 290-296
CrossRef132
Stephen J. Richards, Peter Hillmen. 2002. Immunophenotypic Analysis of PNH Cells. .
CrossRef133
MA Brown, L Mcmahon. (2002) Differentiating paroxysmal nocturnal haemoglobinuria and pre-eclampsia in pregnancy. Nephrology 7, S36-S39
CrossRef134
MA BROWN, L MCMAHON. (2002) Differentiating paroxysmal nocturnal haemoglobinuria and pre-eclampsia in pregnancy. Nephrology 7:s1, S36-S39
CrossRef135
Taroh Kinoshita. 2002. Phosphatidyl Inositol Glycan-A ( PIG-A ) Gene. .
CrossRef136
Galina L. Mukhina, J. Thomas Buckley, James P. Barber, Richard J. Jones, Robert A. Brodsky. (2001) Multilineage glycosylphosphatidylinositol anchor-deficient haematopoiesis in untreated aplastic anaemia. British Journal of Haematology 115:2, 476-482
CrossRef137
David J. Araten, David Swirsky, Anastasios Karadimitris, Rosario Notaro, Khedoudja Nafa, Monica Bessler, Howard T. Thaler, Hugo Castro-Malaspina, Barrett H. Childs, Farid Boulad, Mark Weiss, Nikolaos Anagnostopoulos, Abdullah Kutlar, David G. Savage, Richard T. Maziarz, Suresh Jhanwar, Lucio Luzzatto. (2001) Cytogenetic and morphological abnormalities in paroxysmal nocturnal haemoglobinuria. British Journal of Haematology 115:2, 360-368
CrossRef138
Antonio Cano, W.Marchien Van Baal. (2001) The mechanisms of thrombotic risk induced by hormone replacement therapy. Maturitas 40:1, 17-38
CrossRef139
Debra A. Goldstein, Lars Mouritsen, Steven Friedlander, Howard H. Tessler, Deepak P. Edward. (2001) Acute Endogenous Endophthalmitis Due to Bartonella henselae. Clinical Infectious Diseases 33:5, 718-721
CrossRef140
K Soulier, I Delèvaux, M André, Le Thi Huong Du, J.L Dupond, J.C Piette, O Aumaître. (2001) Thromboses veineuses mésentériques : apports diagnostiques du scanner abdominal et de la recherche d’une coagulopathie. Six observations. La Revue de Médecine Interne 22:8, 699-705
CrossRef141
U. Oelschlaegel, I. Besson, C. Arnoulet, D. Sainty, R. Nowak, R. Naumann, Y. Bux, G. Ehninger. (2001) A standardized flow cytometric method for screening paroxysmal nocturnal haemoglobinuria (PNH) measuring CD55 and CD59 expression on erythrocytes and granulocytes. Clinical and Laboratory Haematology 23:2, 81-90
CrossRef142
Jan Durig, Armin Giese, Ute Schmucker, Hans A. Kretzschmar, Ulrich Duhrsen. (2001) Decreased prion protein expression in human peripheral blood leucocytes from patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology 112:3, 658-662
CrossRef143
Wendell F. Rosse. (2001) New insights into paroxysmal nocturnal hemoglobinuria. Current Opinion in Hematology 8:2, 61-67
CrossRef144
Daniela Matei, Benjamin Brenner, Victor J. Marder. (2001) Acquired thrombophilic syndromes. Blood Reviews 15:1, 31-48
CrossRef145
Junichiro Watanabe, Haruki Kondo, Hisayo Iwazaki, Kiyohiko Hatake, Noboru Horikoshi. (2001) An Unusual Association of Monoclonal Gammopathy, Paroxysmal Nocturnal Haemoglobinuria and Myelodysplastic Syndrome Transformed into Acute Myeloid Leukaemia: Coexistence of Triple Clonal Disorders. Leukemia & Lymphoma 42:4, 813-817
CrossRef146
Karl A Nath, Gregory M Vercellotti, Joseph P Grande, Hiroko Miyoshi, Carlos V Paya, J Carlos Manivel, Jill J Haggard, Anthony J Croatt, William D Payne, Jawed Alam. (2001) Heme protein-induced chronic renal inflammation: Suppressive effect of induced heme oxygenase-11. Kidney International 59:1, 106-117
CrossRef147
P.Aiden McCormick, Karen M. Murphy. (2000) Splenomegaly, hypersplenism and coagulation abnormalities in liver disease. Best Practice & Research Clinical Gastroenterology 14:6, 1009-1031
CrossRef148
Anastasios Karadimitris, Rosario Notaro, Gunther Koehne, Irene A. G. Roberts, Lucio Luzzatto. (2000) PNH cells are as sensitive to T-cell-mediated lysis as their normal counterparts: implications for the pathogenesis of paroxysmal nocturnal haemoglobinuria. British Journal of Haematology 111:4, 1158-1163
CrossRef149
Peter Hillmen, Stephen Richards. (2000) Paroxysmal Nocturnal Hemoglobinuria- the Selection of a Clone. Reviews in Clinical and Experimental Hematology 4:3, 216-235
CrossRef150
Adil M. Choudhary, David Grayer, Alan Nelson, Ingram Roberts. (2000) Mesenteric Venous Thrombosis. Journal of Clinical Gastroenterology 31:2, 179-182
CrossRef151
Stephen J. Richards, Andrew C. Rawstron, Peter Hillmen. (2000) Application of flow cytometry to the diagnosis of paroxysmal nocturnal hemoglobinuria. Cytometry 42:4, 223-233
CrossRef152
S. E. Ball. (2000) The modern management of severe aplastic anaemia. Review. British Journal of Haematology 110:1, 41-53
CrossRef153
Peter Hillmen, Stephen J. Richards. (2000) IMPLICATIONS OF RECENT INSIGHTS INTO THE PATHOPHYSIOLOGY OF PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA. British Journal of Haematology 108:3, 470-479
CrossRef154
Piernicola Boccuni, Luigi Del Vecchio, Rosa Di Noto, Bruno Rotoli. (2000) Glycosyl phosphatidylinositol (GPI)-anchored molecules and the pathogenesis of paroxysmal nocturnal hemoglobinuria. Critical Reviews in Oncology/Hematology 33:1, 25-43
CrossRef155
Koichi Hattori, Takao Hirano, Kazuo Oshimi. (2000) Protease inhibitors and haptoglobin for treatment of renal failure in paroxysmal nocturnal hemoglobinuria. American Journal of Hematology 63:1, 61-62
CrossRef156
Val??rie Biousse. (1999) Coagulation abnormalities and their neuro-ophthalmologic manifestations. Current Opinion in Opthalmology 10:6, 382-393
CrossRef157
Jun-ichi Nishimura, Yoshiko Murakami, Taroh Kinoshita. (1999) Paroxysmal nocturnal hemoglobinuria: An acquired genetic disease. American Journal of Hematology 62:3, 175-182
CrossRef158
Motowo Tomita. (1999) Biochemical background of paroxysmal nocturnal hemoglobinuria. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1455:2-3, 269-286
CrossRef159
Rawstron, Rollinson, Richards, Short, English, Morgan, Hale, Hillmen. (1999) The PNH phenotype cells that emerge in most patients after CAMPATH-1H therapy are present prior to treatment. British Journal of Haematology 107:1, 148-153
CrossRef160
Nobuko Kanai, Theresa M. Vreeke, Charles J. Parker. (1999) Paroxysmal nocturnal hemoglobinuria: Analysis of the effects of mutantPIG-A on gene expression. American Journal of Hematology 61:4, 221-231
CrossRef161
Haruhiko Ninomiya, Yasuko Kawashima, Yuichi Hasegawa, Toshiro Nagasawa. (1999) Complement-induced procoagulant alteration of red blood cell membranes with microvesicle formation in paroxysmal nocturnal haemoglobinuria (PNH): implication for thrombogenesis in PNH. British Journal of Haematology 106:1, 224-231
CrossRef162
Epstein, Franklin H., , Rosenberg, Robert D., Aird, William C., . (1999) Vascular-Bed–Specific Hemostasis and Hypercoagulable States. New England Journal of Medicine 340:20, 1555-1564
Full Text163
B. żupańska, I. Bogdanik, J. Fabijanska-Mitek, H. Pyl. (1999) Autoimmune haemolytic anaemia with a paroxysmal nocturnal haemoglobinuria-like defect. European Journal of Haematology 62:5, 346-349
CrossRef164
A. Tiede, I. Bastisch, J. Schubert, P. Orlean, R. E. Schmidt. (1999) Biosynthesis of Glycosylphosphatidylinositols in Mammals and Unicellular Microbes. Biological Chemistry 380:5, 503-524
CrossRef165
Radovan Saso, Judith Marsh, Lidija Cevreska, Jeffrey Szer, Robert Peter Gale, Philip Rowlings, Jakob Passweg, Melodee Nugent, Lucio Luzzatto, Mary Horowitz, Edward Gordon-Smith. (1999) Bone marrow transplants for paroxysmal nocturnal haemoglobinuria. British Journal of Haematology 104:2, 392-396
CrossRef166
Subhas C. Ganguli, Nizar N. Ramzan, Michael A. McKusick, James C. Andrews, Robert L. Phyliky, Patrick S. Kamath. (1998) Budd-chiari syndrome in patients with hematological disease: A therapeutic challenge. Hepatology 27:4, 1157-1161
CrossRef167
C.H. Packman. (1998) Pathogenesis and management of paroxysmal nocturnal haemoglobinuria. Blood Reviews 12:1, 1-11
CrossRef168
Wendell F. Rosse. (1997) Paroxysmal Nocturnal Hemoglobinuria as a Molecular Disease. Medicine 76:2, 63-93
CrossRef169
Christoph F. Ebenbichler, Reinhard Würzner, Anton D. Sandhofer, Dietger Niederwieseri, Manfred P. Dierich, Josef R. Patsch. (1997) Anti-thymocyte globulin treatment of a patient for paroxysmal nocturnal haemoglobinuria-aplastic anaemia syndrome: complement activation and transient decrease of the PNH clone. Immunobiology 196:5, 513-521
CrossRef170
William J. Harrington, Luciano Kolodny, Lawrence L. Horstman, Wenche Jy, Yeon S. Ahn. (1997) Danazol for paroxysmal nocturnal hemoglobinuria. American Journal of Hematology 54:2, 149-154
CrossRef171
Lucio Luzzatto, Monica Bessler, Bruno Rotoli. (1997) Somatic Mutations in Paroxysmal Nocturnal Hemoglobinuria: A Blessing in Disguise?. Cell 88:1, 1-4
CrossRef172
Charles J. Parker. (1996) Molecular Basis of Paroxysmal Nocturnal Hemoglobinuria. Stem Cells 14:4, 396-411
CrossRef173
Y Poinsignon, G de Charnace, C Arfi, Z Marjanovic, P Bourrier, ML Scrobohaci, MC Boffa, G Socie, E Gluckman, D Valla, D Farge. (1996) Ictère fébrile chez un Cap-Verdien. La Revue de Médecine Interne 17, s284-s285
CrossRef
